About me
Kevin co-founded Contraline and has been CEO since its inception in 2015. Contraline is a medical device company developing paradigm-shifting innovations in reproductive health, starting with the world's first long-lasting, reversible male contraceptive known as ADAM. Kevin has led Contraline from an idea to a clinical-stage company and has raised >$20M in financing from investors such as GV and Founders Fund.
Kevin's research background is in immunotherapy and reproductive biology. He is an inventor with 36 patents relating to novel contraceptive drugs and devices, surgical devices, and biomaterials. His degree is in Nanomedicine Engineering from the University of Virginia, and in 2017, was named on the Forbes 30 Under 30 in Healthcare. Kevin is also an active angel investor and startup advisor, with a focus on biotech and deep tech companies.
Twitter
LinkedIn
